摘要
2019年4月美国食品药品监督管理局(FDA)正式批准ASCENIV(RI-002)上市用于治疗成人和青少年(12~17岁)原发性体液免疫缺陷,ASCENIV是一种多克隆、含10%人-slra的新型静脉注射用免疫球蛋白(IG)。其多克隆IG组成具有更强的中和抗呼吸道合胞病毒(RSV)活性。不仅如此,有临床前数据显示ASCENIV还可用于其他呼吸道病原体的体液保护。现对其作用机制、药效学、药动学、临床研究、安全性和注意事项等作一综述。
The US Food and Drug Administration(FDA)officially approved the marketing of ASCENIV(RI-002)for the treatment of primary humoral immune deficiency disease("PIDD")in adults and adolescents(12-17 years old)on April 2019.ASCENIV,Human-slra 10%Liquid,is a polyclonal immune globulin intravenous(IG),its polyclonal IG composition has stronger neutralizing anti-respiratory syncytial virus(RSV)activity,and preclinical data show that ASCENIVTM can be used for humoral protection of other respiratory pathogens.Now,we reviewed the mechanism of action,pharmacodynamics,pharmacokinetics,clinical research,safety and precautions about ASCENIV.
作者
曹璐
何心
许静
CAO Lu;HE Xin;XU Jing(Department of Pharmacy,Children's Hospital of Nanjing Medical University,Nanjing 210008,Jiangsu Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第8期1020-1023,共4页
The Chinese Journal of Clinical Pharmacology